
RFL — Rafael Holdings, Inc.
NYSE · Real Estate · Real Estate Services
$2.50
+$0.06 (+2.46%)
Rafael Holdings, Inc. (RFL) is a real estate services company listed on NYSE. It is led by Howard S. Jonas, based in 520 Broad Street, Newark, NJ, United States, 07102, with about 28 employees. Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Latest reported RFL revenue for 2025-07-31 was $30.0K. Net income was -$30.6M. Revenue was down 91.7% from 2025-04-30 to 2025-07-31. RFL currently screens at market cap $66.3M.
Use this RFL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RFL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RFL SEC filings page. Lician reads the product cache first so this HTML stays unique to Rafael Holdings, Inc. even when a live quote feed is slow.
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
RFL Key Statistics
Market Cap
$66.34M
Volume
304,587
Previous Close
$2.37
Day Range
$2.39 – $2.82
EPS
-$1.04
Revenue
$30.00K
Net Income
-$30.64M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-95.3%
Profit Margin
-102143.3%
Employees
28
RFL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $30.00K | $637.00K | $279.00K | $410.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$30.64M | -$65.00M | -$2.21M | -$142.38M |
| EPS (Diluted) | -$1.04 | -$1.45 | -$0.08 | -$6.31 |
Total Assets
$114.11M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$52.77M
Operating Cash Flow
-$18.92M
Free Cash Flow
$0.00
Rafael Holdings, Inc. Company Information
- CEO, Founder & Executive Chairman
- Howard S. Jonas
- Headquarters
- 520 Broad Street, Newark, NJ, United States, 07102
- Website
- www.rafaelholdings.com
- Phone
- 212 658 1450
- IPO / Founded
- 2018-03-26
- Sector
- Real Estate
- Industry
- Real Estate Services